These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 8837544

  • 1. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A, Adachi J, Olszynski W.
    CMAJ; 1996 Oct 01; 155(7):945-8. PubMed ID: 8837544
    [Abstract] [Full Text] [Related]

  • 2. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.
    CMAJ; 1996 Oct 15; 155(8):1113-33. PubMed ID: 8873639
    [Abstract] [Full Text] [Related]

  • 3. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM, Ste-Marie LG.
    CMAJ; 1996 Oct 01; 155(7):949-54. PubMed ID: 8837545
    [Abstract] [Full Text] [Related]

  • 4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
    Siminoski K, Josse RG.
    CMAJ; 1996 Oct 01; 155(7):962-5. PubMed ID: 8837547
    [Abstract] [Full Text] [Related]

  • 5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
    Jones G, Hogan DB, Yendt E, Hanley DA.
    CMAJ; 1996 Oct 01; 155(7):955-61. PubMed ID: 8837546
    [Abstract] [Full Text] [Related]

  • 6. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
    Josse RG.
    CMAJ; 1996 Oct 01; 155(7):929-34. PubMed ID: 8837542
    [Abstract] [Full Text] [Related]

  • 7. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis.
    Murray TM.
    CMAJ; 1996 Oct 01; 155(7):935-9. PubMed ID: 8837543
    [Abstract] [Full Text] [Related]

  • 8. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr 01; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul 01; 44(7):1496-503. PubMed ID: 11465699
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.
    Curr Med Res Opin; 2007 Oct 01; 23(10):2517-29. PubMed ID: 17825128
    [Abstract] [Full Text] [Related]

  • 11. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S.
    Clin Ther; 2006 Feb 01; 28(2):151-73. PubMed ID: 16678639
    [Abstract] [Full Text] [Related]

  • 12. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 13. [Use of bisphosphates in treatment of primary and secondary osteoporosis].
    Olszyński WP.
    Pol Tyg Lek; 1995 Nov 13; 50(44-47):56-8. PubMed ID: 8643431
    [Abstract] [Full Text] [Related]

  • 14. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
    Woo T, Adachi JD.
    Best Pract Res Clin Rheumatol; 2001 Jul 13; 15(3):469-81. PubMed ID: 11485341
    [Abstract] [Full Text] [Related]

  • 15. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
    Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada.
    CMAJ; 2002 Nov 12; 167(10 Suppl):S1-34. PubMed ID: 12427685
    [Abstract] [Full Text] [Related]

  • 16. Management of osteoporosis due to ovarian failure.
    Eastell R.
    Med Pediatr Oncol; 2003 Sep 12; 41(3):222-7. PubMed ID: 12868123
    [Abstract] [Full Text] [Related]

  • 17. Clinical trials with bisphosphonates.
    Lombardi A, Santora AC.
    Ann Ital Med Int; 1992 Sep 12; 7(3 Suppl):158S-165S. PubMed ID: 1297394
    [Abstract] [Full Text] [Related]

  • 18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 12; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM, Carson DS, Barrington R.
    J Fam Pract; 2000 Sep 12; 49(9):839-48. PubMed ID: 11032210
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May 12; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.